Astex Earns Milestone Payment on Initiation of Phase 3 Study

05-03-2014 Business Wire HealthComments (0)

Astex PharmaceuticalsPharmaceuticalUSA

Astex Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that it has received a milestone payment triggered by the commencement, by Novartis, of a Phase 3 study of LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4 and 6. LEE011 was discovered as part of a drug discovery collaboration between Astex and Novartis announced in December 2005. LE

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top